Teriparatide (PTH 1-34) Research Overview

What Is Teriparatide?

Teriparatide is a recombinant analogue of the first 34 amino acids of endogenous human parathyroid hormone (PTH), designated PTH(1–34). It is marketed under the brand name Forteo (Eli Lilly) and was the first anabolic bone agent approved by the U.S. Food and Drug Administration (FDA). Unlike antiresorptive agents that primarily slow bone loss, teriparatide actively stimulates new bone formation, classifying it as an osteoanabolic therapy.

The full-length PTH molecule contains 84 amino acids. The biologically active N-terminal fragment — residues 1 through 34 — is sufficient to activate PTH type 1 receptors (PTH1R) and produce the complete anabolic bone response. Teriparatide has a molecular weight of approximately 4117.8 Da and is administered as a subcutaneous injection.

Mechanism of Action

Teriparatide binds to the PTH1 receptor expressed on osteoblasts and osteocytes. When administered as an intermittent (once-daily) pulse, rather than as a continuous infusion, PTH(1–34) exerts a net anabolic effect. The pulsatile exposure preferentially drives osteoblast proliferation and survival while suppressing osteoblast apoptosis, resulting in net bone formation that outpaces resorption.

At the molecular level, PTH1R activation triggers cyclic AMP-PKA and phospholipase C-PKC signaling cascades. These pathways upregulate IGF-1 and Wnt signaling locally, promote differentiation of mesenchymal progenitors into mature osteoblasts, and modulate sclerostin and DKK1 expression. The resulting increase in bone mineral density occurs at both trabecular and cortical sites, though the trabecular response is more pronounced.

Importantly, the anabolic effect is dose- and frequency-dependent. Continuous PTH exposure (as occurs in primary hyperparathyroidism) produces a catabolic net effect on cortical bone, whereas intermittent daily injections produce the opposite. This distinction is central to understanding teriparatide's therapeutic profile.

Key Clinical Research

The Neer 2001 Fracture Prevention Trial

The pivotal trial establishing teriparatide's efficacy was published by Neer and colleagues in the New England Journal of Medicine in 2001 (PMID: 11346808). This randomized, double-blind, placebo-controlled trial enrolled 1,637 postmenopausal women with at least one prior vertebral fracture and low bone mineral density (BMD). Participants received subcutaneous teriparatide 20 mcg/day, 40 mcg/day, or placebo for a median of 21 months.

The 20 mcg/day group demonstrated a 65% relative risk reduction in new vertebral fractures compared with placebo (relative risk 0.35; 95% CI 0.22–0.55) and a 53% reduction in nonvertebral fragility fractures. Lumbar spine BMD increased by 9.7% and femoral neck BMD by 2.8% over the treatment period. The trial was stopped early by the data safety monitoring board following osteosarcoma findings in a concurrent rat study, though no osteosarcoma cases occurred in the human cohort.

Glucocorticoid-Induced Osteoporosis

A subsequent NEJM trial (Saag et al., 2007, PMID: 18046026) demonstrated teriparatide's superiority over alendronate in glucocorticoid-induced osteoporosis. At 18 months, teriparatide produced greater increases in lumbar spine BMD and significantly fewer new vertebral fractures compared with alendronate.

Post-Market Osteosarcoma Surveillance

Following FDA approval in 2002, Eli Lilly conducted a 15-year post-market surveillance program (2003–2019) tracking osteosarcoma incidence in approximately 2.47 million teriparatide-treated patients. The incidence rate of osteosarcoma did not exceed the background population rate. This data, published in Bone (2022), contributed to the FDA's November 2020 decision to remove the boxed warning and the prior 2-year lifetime treatment limitation from the Forteo label.

Pharmacokinetics

Teriparatide is administered subcutaneously. Peak serum concentrations are reached approximately 30 minutes after injection. The elimination half-life is roughly 1 hour when given subcutaneously, reflecting both absorption kinetics and enzymatic cleavage by peripheral proteases. It is not renally cleared as an intact peptide; nonspecific proteolytic degradation in the liver and peripheral tissues accounts for most elimination. No dose adjustment is required for mild-to-moderate renal impairment, though severe renal impairment warrants caution per the FDA label.

Absolute bioavailability following subcutaneous injection is approximately 95%. The volume of distribution is approximately 0.12 L/kg, indicating distribution mainly to extracellular fluid. Teriparatide does not bind appreciably to plasma proteins. There are no known clinically significant drug-drug interactions mediated by cytochrome P450 enzymes.

FDA-Approved Indications and Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The FDA label specifies teriparatide (Forteo) at a dose of 20 mcg once daily via subcutaneous injection, used for:

1. Postmenopausal women with osteoporosis at high fracture risk, including those who have failed or are intolerant of other available osteoporosis therapy.

2. Men with primary or hypogonadal osteoporosis at high fracture risk.

3. Men and women with glucocorticoid-induced osteoporosis at high fracture risk.

Following the November 2020 label update, the previous restriction limiting use to a cumulative 2-year lifetime maximum was removed. The 2024 updated Forteo label (NDA 021318) reflects this change. Prior to 2020, the label also carried a boxed warning regarding osteosarcoma risk based on rat studies at supratherapeutic doses; this warning was eliminated following completion of the post-market surveillance program.

Storage and Stability

Forteo prefilled pens should be stored at 2–8 °C (36–46 °F) in a refrigerator at all times. The FDA label instructs that the pen should be returned to the refrigerator immediately after each use. Do not freeze; do not use if frozen. The 3-mL delivery device contains 28 doses. Once a pen is in use, it may be kept at 2–8 °C for up to 28 days.

What Teriparatide Is Not

Teriparatide is not the same as full-length PTH(1–84), which is marketed as Preotact/Natpara for a different indication (hypoparathyroidism). It is not an antiresorptive agent such as a bisphosphonate or denosumab; its mechanism is fundamentally anabolic. Teriparatide is not a growth hormone secretagogue and does not stimulate the GH/IGF-1 axis directly, despite the fact that it modulates local IGF-1 production in bone tissue. It is a prescription-only medication regulated under the FDA drug approval framework — not a research peptide sold by unregulated vendors.

Teriparatide should not be confused with abaloparatide (Tymlos), a PTH-related protein analogue with a distinct receptor selectivity profile approved for similar indications.

References

See citations below.